ABRE Study Meets Primary Safety and Effectiveness Endpoints

NEXT STORY
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
PREV STORY
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

author_avatar
NASDAQ Market News

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs

author_avatar
NASDAQ Market News

HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

author_avatar
NASDAQ Market News